

CLINICAL DOCUMENTATION: ARRHYTHMIA

THE DIAGNOSIS	Arrhythmia
COMMON CONDITIONS INCLUDED IN HCC GROUP: 238 RAF score = 0.299	Atrioventricular block, complete – I44.2 Paroxysmal tachycardia, unspecified – I47.9 Paroxysmal atrial fibrillation – I48.0 Longstanding persistent atrial fibrillation – I48.11 Chronic atrial fibrillation, unspecified – I48.20 Permanent atrial fibrillation – I48.21 Typical atrial flutter - I48.3 Sick Sinus Syndrome – I49.5
KEY CODING or DOCUMENTATION TIPS	<p>If the patient's a-fib is known to be persistent, longstanding, or permanent, please do not use the unspecified diagnosis code (I48.20).</p> <p>The recommended diagnosis for "Chronic persistent atrial fibrillation" is I48.19 or "Other persistent a-fib".</p>
MEAT the DOCUMENTATION M= Monitor E = Evaluate A = Assess/Address T = Treat	<p>Assessment and Plan example:</p> <p>Longstanding atrial fibrillation (I48.11)</p> <p>Long term (current) use anticoagulants (Z79.01)</p> <p>Mrs. R is a 72-yo female who presents for her AWW. She saw her cardiologist, Dr. C, last month. Recent EKG continues to show chronic a-fib, despite cardioversion attempt last year. Per cardiology note, no changes in her medications. Pt is tolerating her rivaroxaban without incident. Pt's activity level is good for ADLs yet limited regarding exercise. She gets a little dizzy and c/o SOB. Follow-up in 4 months.</p> <p>M – Signs and symptoms, such as shortness of breath, dizziness.</p> <p>E – Test results or vital signs, such as EKG review.</p> <p>A – Order tests or patient discussion, such as ordering an exercise tolerance stress test.</p> <p>T – Medications, therapy, or other modalities, such as rivaroxaban.</p>
IMPACT on QUALITY – HEDIS MEASURES	<p>CMS 156 – Use of High-Risk Medications in Older Adults</p> <ul style="list-style-type: none"> Anticoagulants are considered a high-risk medication. If two or more high-risk medications are prescribed for the patient, then the patient will be in the denominator for this quality metric. <p>CMS 326 – A-fib and A-flutter: Chronic Anticoagulation Therapy</p> <ul style="list-style-type: none"> Submit once or more per performance period. If patient has a documented CHA₂DS₂-VASc score, then they are excluded from this quality metric.